Health Care/Hospital
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...
2026-09-09 19:12
2393
Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026
Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc....
2026-09-09 18:30
1679
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...
2026-09-09 18:00
1754
Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation
SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded nutraceutical solution platform into the growing sleep wellness category with the introduction of NF TriSolve® SleepRestore ...
2026-09-08 22:00
2596
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...
2026-09-08 21:00
2850
GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay
NEW YORK, Sept. 8, 2026 /PRNewswire/ -- GROWNSY, a baby care brand trusted by more than 3 million households worldwide, today announced a new long-term partnership with Graham's Foundation, a nonprofit organization dedicated to supporting parents of premature babies. The partnership will begin d...
2026-09-08 21:00
1873
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...
2026-09-08 20:20
1746
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...
2026-09-08 20:17
2107
Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended J...
2026-09-08 18:00
5275
/C O R R E C T I O N -- GCCL/
In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name "Yoo-Hwa Choi" should read "Yuhwa Choi" throughout the release, as originally issued inadvertently. Co...
2026-09-08 16:05
2449
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clini...
2026-09-08 08:00
1855
U.S. District Court Invalidates Kaneka's Ubiquinol Patent, Clearing the Way for Cocrystal Tech's CrysQnol™ in the U.S. Market
Judge Overturns Kaneka's '080 Patent for Lack of Utility and Enablement, Removing Legal Uncertainty for Customers and Partners JIAXING, China, Sept. 7, 2026 /PRNewswire/ -- Cocrystal Technology (Jiaxing) Co., Ltd. ("Cocrystal Tech")today announced that the U.S. District Court for the Eastern Dis...
2026-09-07 20:30
4343
Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026 /PRNe...
2026-09-07 20:00
3143
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...
2026-09-07 17:42
2620
CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities
YANTAI, China, Sept. 7, 2026 /PRNewswire/ -- CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achievedEXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media supplier to r...
2026-09-07 14:00
1885
Prof Kevin Plaxco joins Nutromics as Chief Scientific Officer, bolstering expansion efforts for the DNA-based sensing platform
MELBOURNE, Australia, Sept. 7, 2026 /PRNewswire/ -- Nutromics, a Melbourne-based startup leading the frontier of DNA-based sensing, has announced the appointment of Professor Kevin W. Plaxco as Chief Scientific Officer (CSO). The company is preparing for the launch of its first product in 2027, ...
2026-09-07 13:14
2520
Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research
SEONGNAM, South Korea, Sept. 6, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in the high-efficiency production of circular RNA (circRNA) – a rapidly emerging modality ...
2026-09-07 12:36
1919
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today ann...
2026-09-07 08:46
2307
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust neutralizing a...
2026-09-07 07:07
2444
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The share...
2026-09-07 07:00
5564
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23044
